Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6xNHY2yqEQvF2= NYLSdW45PDkEoHi= NIjQVlJjdG:la4OgNlcuV0iFLXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHPvcZBiemGkbHWgeI8hfGijdDDv[kBj[XOjbDDs[ZZmdHN? MWeyOlM2ODV4NR?=
NP69 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[3TWM2OD1|MT62PeKyOi53NDFOwG0> NYPKUZNLOjZ{NUK1O|U>
NP460 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LwdGlEPTB;MkKuPFXDuTFwMUig{txO NG\zOoczPjJ3MkW3OS=>
C666-1 NFXPb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn3W5hnUUN3ME2xPU46PcLzOD65N{DPxE1? NUTLfYNbOjZ{NUK1O|U>
C666-1 MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYCxNEDDvU1? MnXPOFghcA>? NFTQe4ZFVVOR NX7tXGVTe2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gZ4l{eGyjdHnu NY[5c|Z{OjZ{NUK1O|U>
C666-1  MX3GeY5kfGmxbjDBd5NigQ>? M4G2cFExKML3TR?= NEfiTmEzPCCq MVvEUXNQ M2jMU4FkfGm4YYTld{B1cGVicEWzJJBifGi5YYmsJJVxemWpdXzheIlv\yCyNUOsJJAzOSCjbnSgUYRuOg>? M2j1fVI3OjV{NUe1
C666-1 NGDwd2hCeG:ydH;zbZMhSXO|YYm= NYS5Oll7OTBiwsXN MV20PE84OiCq Mo\qSG1UVw>? M174epNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJINqe3CuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MYmyOlI2OjV5NR?=
A549 M{fQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\1SlgzPCCq NYW2e4xTUUN3ME2xO{43QCEEsTC0MlUzKM7:TR?= MofFNlYyOjV{M{C=
A549-NTC MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHrSFdQOjRiaB?= NFPH[HVKSzVyPUG5MlQzKMLzIEGuPVYh|ryP NHnMSVYzPjF{NUKzNC=>
A549-920 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPtNlQhcA>? NIi3R4FKSzVyPUOzMlg2KMLzIESuPFQh|ryP NYXwZWttOjZzMkWyN|A>
CRL-5908 M165R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13nflI1KGh? NWnqbHR4UUN3ME2zPE44OSEEsTCyMlQ{KM7:TR?= M1vIO|I3OTJ3MkOw
L6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[3WWFMOTEEoN88UeKh Mn;tNlQwPDhxN{KgbC=> NGjQVZVFVVOR NGny[oNqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? NFXpTpUzPTh5MUe5OC=>
C2C12 NYPvWVlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHJcY4yOMLizszNxsA> M3q4OFI1NzR6L{eyJIg> NFXTWplFVVOR NVjEcmtKcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w NGj4WYMzPTh5MUe5OC=>
MCF-7  M1XvbmZ2dmO2aX;uJGF{e2G7 NETLZlMyOMLizszN MlLUSG1UVw>? Mo\ibY5pcWKrdIOgZ5lkdGmwIFSxJIFv\CCGaXPlduKh MXuyOVcxOjdyMx?=
DU4475  MofhSpVv[3Srb36gRZN{[Xl? M1PCR|UwOTBxMkCg{txO MlHCNlTDqGh? M1S2e4Rwf26{ZXf1cIF1\XNiVH;jZU0yKGSxc3Wg[IVx\W6mZX70cJk> NGPsU5ozPTV2N{G3OC=>
SMMC-7721 M4HSfWZ2dmO2aX;uJGF{e2G7 Mn;oNVAh|ryP NXG4bGdPPDhiaB?= M{\1UmROW09? Mor3Z4F2e2W|IFTORUBFW0JiZHHtZYdm Mn\qNlU2PDR|NkG=
SMMC-7721 NW\iN4FtTnWwY4Tpc44hSXO|YYm= M4mxXVExKM7:TR?= NIHaOpg1QCCq M1uwSWROW09? NES5WG1qdmS3Y3XzJJRp\SClaILvcYF1cW5vYn;1coQheHKxdHXpckBKTklzNjD0c{Bx[XK2aXHscJkhdG:lYXzpfoUhcW5idHjlJIN6fG:ybHHzceKh M{HzbFI2PTR2M{[x
SMMC-7721 NY\JfZZOTnWwY4Tpc44hSXO|YYm= NVK2SVNROTBizszN Mnn1OFghcA>? MoT2SG1UVw>? M3rZZolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZtMgTWZPSjIEoH3SUmE> MUCyOVU1PDN4MR?=
SMMC-7721 NHHWS4dHfW6ldHnvckBCe3OjeR?= MorJNVAh|ryP MoXuN|YhcA>? NIXRNoJFVVOR MofMZ4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY> M1PCU|I2PTR2M{[x
MCF-7 MV;GeY5kfGmxbjDBd5NigQ>? M4fETlExyqEQvF2= NHnhZnYxNTJ2IHi= NU\xenczcW6mdXPld{BxPTNiYX7kJJAzOS:FaYCx M4PzW|I2PDh{M{ez
OVCAR10 NX30V5VoTnWwY4Tpc44hSXO|YYm= NFi0VYoyOMLizszN NXXEOmV4OjGqwrC= Mn;HSG1UVw>? MnPmbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> MXeyOVQzPjV2OB?=
NCI-H23 Ml7TSpVv[3Srb36gRZN{[Xl? NGHLTZEyOMLizszN MlHNNlFpyqB? NGPE[VNFVVOR NHnTZnhqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ Ml7MNlU1OjZ3NEi=
A2780 MmPoSpVv[3Srb36gRZN{[Xl? MXexNOKh|ryP NYPhcotYOjGqwrC= M2\XTGROW09? M2PHRYlv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> NULaZ|hVOjV2Mk[1OFg>
NCI-H23 NV7Gd5o5TnWwY4Tpc44hSXO|YYm= MlTONVDDqM7:TR?= MUSyNYjDqA>? M37nSWROW09? NG\uNWxl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> NXW0eFFHOjV2Mk[1OFg>
A2780 NG\sRYFHfW6ldHnvckBCe3OjeR?= NVLVbWJIOTEEoN88US=> MU[yNYjDqA>? M1\1SmROW09? Mmm0[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO= M2rKOlI2PDJ4NUS4
HCT116  M{Dk[2Z2dmO2aX;uJGF{e2G7 NI\iV4syOCEEtV2= M37URVI1KGh? MmDCZ4F2e2W|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6 Mnv2NlU{QDByNUW=
MCF-10CA1a MkG3SpVv[3Srb36gRZN{[Xl? M2G0cFExyqEQvF2= NX7mT45iPDhiaB?= MlPiSG1UVw>? NYfxe5lFcW6qaXLpeJMh[mG|YXygbY53[XOrb36gZY5lKHKnZIXj[YQhXEeILd8yN{1qdmS3Y3XkJIlvfmG|aX;uJJRwKGKjc3HsJIxmfmWucx?= MorpNlUzPTd5Mkm=
MCF-10A1  MXPGeY5kfGmxbjDBd5NigQ>? MVKxNOKh|ryP NHXBbpIzPC92ODDo MYPEUXNQ M3rzbYlvcGmkaYTzJI1q\3KjdHnvckBw\iCwb4LtZYwh[nKnYYP0JIVxcXSqZXzpZYzDqA>? MYGyOVI2Pzd{OR?=
MCF-10CA1a M1PCfGZ2dmO2aX;uJGF{e2G7 M3HnNlExyqEQvF2= MkXWNlQhcA>? NEfQXlhFVVOR M4[0V4Rm[3KnYYPld{B1cGViVFfGMe6zOy2rbnT1Z4VlKG2UTlGgcIV3\Wy|IH;mUW1ROi{EoF3NVFktKGGwZNMgbY51\We{aX9CpO6zyqB| NXjl[HhFOjV{NUe3Nlk>
MCF-10CA1a MXLGeY5kfGmxbjDBd5NigQ>? NFXaenMyOMLizszN MoHDNlQhcA>? NInLRmdFVVOR M4HNfIlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NHLwdY4zPTJ3N{eyPS=>
SK-BR-7 NXTpRVdxTnWwY4Tpc44hSXO|YYm= NVTnNZA4OTEEoN88US=> NGO5cI4zPCCq NF\QToFFVVOR MlrPbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NF;aVpkzPTJ3N{eyPS=>
SUM102PT MkXkSpVv[3Srb36gRZN{[Xl? MVOxNOKh|ryP NVPuUIdVOjRiaB?= NXT0Tnc3TE2VTx?= MWPpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? M4fPUlI2OjV5N{K5
RAW 264.7 MW\GeY5kfGmxbjDBd5NigQ>? MlLaNVDDqM7:TR?= MYOzNEBucW5? NUnnNot6eHKndnXueJMhfGinIIC1N{Bz\WS3Y4Tpc44hcW5icnXzdI9ve2VidH:gUHBU NHWyPIUzPTF5MkW0Oy=>
RAW 264.7 NEC0cIdHfW6ldHnvckBCe3OjeR?= M4L2c|ExyqEQvF2= MnnzN|AhdWmw M1nqV5Jm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm= M3n4R|I2OTd{NUS3
RAW 264.7 MYXGeY5kfGmxbjDBd5NigQ>? MoDaNVDDqM7:TR?= MnW1N|AhdWmw M36wTIlvcGmkaYTzJGxRWy2rbnT1Z4VlKE6RIIDyc4R2[3Srb39CpC=> NUnEPHFTOjVzN{K1OFc>
MCF7  M1LoT2NmdGxiVnnhZoltcXS7IFHzd4F6 NHTjNHgzNjViwsXN MXS1JIQ> NUXQNYxMTE2VTx?= MmPDd4Vve2m2aYrld{BOS0Z5IITvJHBCWlBiaX7obYJqfGmxbh?= M1\HfVI2ODh3OUCy
MCF7  NYjGXppyTnWwY4Tpc44hSXO|YYm= NXjoOm9ZOi53INM1US=> M2DrN|Q5KGh? MlXmSG1UVw>? Moq2[IVkemWjc3XzJJRp\SCqb33vcI9od3W|IFTTRkBz\XCjaYKg[pJmeXWnbnPp[ZM> MVqyOVA5PTlyMh?=
ACHN NUTUUWlJS2WubDDWbYFjcWyrdImgRZN{[Xl? MnTHNE42NTFyIN88US=> MnnYNE03KGR? NYrEPYYzTE2VTx?= MkT0bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYWyOVA3Pzd6Nx?=
Caki-2 NYWyN3duS2WubDDWbYFjcWyrdImgRZN{[Xl? M4fXb|AvPS1zMDFOwG0> M{\pclAuPiCm MnjqSG1UVw>? NIHIRZNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MUSyOVA3Pzd6Nx?=
A498 NIS5O2pE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXywMlUuOTBizszN M3i5XFAuPiCm NIT4TYRFVVOR NH3BSlFqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3fQOVI2ODZ5N{i3
115 M4XoSWNmdGxiVnnhZoltcXS7IFHzd4F6 NIjydIUxNjVvMUCg{txO M4nYRVAuPiCm Mnj2SG1UVw>? NYjyVZl7cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NEXwOHMzPTB4N{e4Oy=>
117 MmXjR4VtdCCYaXHibYxqfHliQYPzZZk> NIrIfVQxNjVvMUCg{txO NIHkNosxNTZiZB?= NEPaSVdFVVOR MYfpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4LUflI2ODZ5N{i3
ACHN NVe4U2p2TnWwY4Tpc44hSXO|YYm= NHTG[I8xNjVxMT:1JO69VQ>? NGDsV3I1QCCq NHnNeGZFVVOR M1ToUYxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz MYeyOVA3Pzd6Nx?=
Caki-2 MkDBSpVv[3Srb36gRZN{[Xl? M2DTPVAvPS9zL{Wg{txO NUPtN4RCPDhiaB?= NVLZUlRlTE2VTx?= NFnwWpVt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MYqyOVA3Pzd6Nx?=
A498 NGHGSYlHfW6ldHnvckBCe3OjeR?= MkT2NE42NzFxNTFOwG0> NWXGdINnPDhiaB?= MUnEUXNQ M1vQdIxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz MVSyOVA3Pzd6Nx?=
115 MlfWSpVv[3Srb36gRZN{[Xl? MkPFNE42NzFxNTFOwG0> NVPZU216PDhiaB?= M1Tu[mROW09? NVzhW5N7dGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= MkPjNlUxPjd5OEe=
ACHN NY[0WVNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK1JO69VQ>? MUi0PEBp Mn;zSG1UVw>? NV3nO5U2cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh MUOyOVA3Pzd6Nx?=
Caki-2 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOydHg2KM7:TR?= Ml3iOFghcA>? NXPx[5dlTE2VTx?= M2HsNIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MkHJNlUxPjd5OEe=
A498 Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofaOUDPxE1? NIT6[ZU1QCCq NHWw[oJFVVOR MWnpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NXLEcIhUOjVyNke3PFc>
115 NH3vW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLBOUDPxE1? NHrTbXQ1QCCq MnTYSG1UVw>? MWnpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NILx[Y4zPTB4N{e4Oy=>
ACHN MkfRSpVv[3Srb36gRZN{[Xl? NWTkUFNzPSEQvF2= MXG0PEBp MlL6SG1UVw>? MUfpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MX6yOVA3Pzd6Nx?=
Caki-2 MVzGeY5kfGmxbjDBd5NigQ>? MoL5OUDPxE1? MUO0PEBp M2m3b2ROW09? NUHXcXp5cW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> M1zDVFI2ODZ5N{i3
A498 NXW5S5V[TnWwY4Tpc44hSXO|YYm= MXK1JO69VQ>? MVW0PEBp MXHEUXNQ NIjVeWRqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg NXOyXYxDOjVyNke3PFc>
115 NXLTcWd3TnWwY4Tpc44hSXO|YYm= MV:1JO69VQ>? MmriOFghcA>? M2PzOWROW09? NIDDcJNqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg NUW4bpB{OjVyNke3PFc>
MOLM-13 NWT5UmdtTnWwY4Tpc44hSXO|YYm= Mn3TOuKh|ryP NWTFVYVTOC16IHi= NYOzZWR{TE2VTx?= NIDnO4pqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDwOVMtKE2GTUKsJJAzOSCjbnSgZYNmfHmuYYTl[EBxPTN? MkTpNlQ5QDVyOEK=
MOLM-13 MmqwSpVv[3Srb36gRZN{[Xl? MWi2xsDPxE1? NH24OGM3KGh? M1i3SmROW09? MUflcohidmOnczD0bIUh[WOndInsZZRqd25ib3[gbIl{fG:wZTDINmIh[W6mIHjlZZQhe2ixY3ugdJJwfGWrboOgTJNxOjdiYX7kJGh{eDly MoDCNlQ5QDVyOEK=
HepG2 NEm1N4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rLTVczKGh? NFW2T|ZFVVOR M4PjV2lEPTB;M{WuPFYhyrFiMj65JO69VQ>? MkK3NlQ5QDR6MEm=
HepG2/As NHO5OG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LYd|czKGh? NFn1S3dFVVOR NIXJcWdKSzVyPU[4MlE{KMLzIEmuOkDPxE1? M17HVVI1QDh2OEC5
SMMC7721 NXrWZmhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPqO|IhcA>? M2DiSmROW09? NE\qNFhKSzVyPUOxMlI5KMLzIESuNkDPxE1? NV\rZ|RXOjR6OES4NFk>
SMMC7721/Ac NGjERVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUi3NkBp NWPLSWE1TE2VTx?= MmrnTWM2OD13NT6yNUDDuSB3LkCzJO69VQ>? NFXxVJAzPDh6NEiwPS=>
Huh-7 NX62SXVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXi3NkBp MlzVSG1UVw>? MoPlTWM2OD1|Mz65OkDDuSB|Lkmg{txO M3rmUVI1QDh2OEC5
Hep3B MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLnO|IhcA>? M3ewN2ROW09? M{PBUGlEPTB;MkCuNVghyrFiMT64OEDPxE1? M{LpcVI1QDh2OEC5
HepG2 MWPBdI9xfG:|aYOgRZN{[Xl? MlnUbY5lfWOnczDhdI9xfG:|aYO= MnL5NlQ5QDR6MEm=
SMMC7721 MX\BdI9xfG:|aYOgRZN{[Xl? MX\pcoR2[2W|IHHwc5B1d3Orcx?= NXi4e5I3OjR6OES4NFk>
Huh-7 NFfiT5JCeG:ydH;zbZMhSXO|YYm= MlLvbY5lfWOnczDhdI9xfG:|aYO= NEj2TGkzPDh6NEiwPS=>
Hep3B MVjBdI9xfG:|aYOgRZN{[Xl? MnjhbY5lfWOnczDhdI9xfG:|aYO= MnzFNlQ5QDR6MEm=
U2OS  NHrWXItHfW6ldHnvckBCe3OjeR?= NGnaZoIzOCEQvF2= NVn6RnY1OjRiaB?= MkPtbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKhSkOOMlGxMEBDS0y[TNMgZY5lSkOOVx?= NWf5OItVOjR6NkeyOVk>
AML2 MnzRRZBweHSxc3nzJGF{e2G7 Mn7tNk8yOCEQvF2= NVK4c3JsOjRxNEigbC=> Mnn4bY5lfWOnczDhdI9xfG:|aYO= MlnENlQ3PTl5NEm=
MOML13 MnLwRZBweHSxc3nzJGF{e2G7 NHLwUmMzNzFyIN88US=> M4PUOlI1NzR6IHi= NYTEc5NbcW6mdXPld{BieG:ydH;zbZM> MVeyOFY2QTd2OR?=
AML2 MnXwSpVv[3Srb36gRZN{[Xl? MUGxNO69VQ>? NVnvNYVpOi92IHi= Ml;QbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= MlvkNlQ3PTl5NEm=
AML3 NI[2TFNHfW6ldHnvckBCe3OjeR?= NIHEUZgyOM7:TR?= M2K1e|IwPCCq M1;KZolv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz M1v0N|I1PjV7N{S5
MOML13 NHvXU4lHfW6ldHnvckBCe3OjeR?= MXyxNO69VQ>? MnLBNk81KGh? M1zldIlv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz M2\3bFI1PjV7N{S5
BeWo NEDQSWZHfW6ldHnvckBCe3OjeR?= NUfVWnBZOzBiwsXN M120WlI1KGh? MoLWbY5kemWjc3XzJJA2OyxiTXTtNkwheDJzIHHu[EBRfW2jIHH0JJRp\SCycn;0[YlvKGyndnXs M4rC[VI1PDl6MUW0
BeWo M4\LeWFxd3C2b4Ppd{BCe3OjeR?= MUOzNEDDvU1? MoLnNlQhcA>? NWTmNmxjcW6lcnXhd4V{KGGyb4D0c5Nqew>? NE\JclUzPDR7OEG1OC=>
OCI NWewV4lYTnWwY4Tpc44hSXO|YYm= MYCxNEDPxE1? NGDhcmIzPCCq MmrkeZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w MkT3NlQ1PzN3NkK=
MOLM NXvwN4Z{TnWwY4Tpc44hSXO|YYm= M{iwfFExKM7:TR?= NGPa[|YzPCCq NYi3O2l4fXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u M4XKTFI1PDd|NU[y
U2OS  NIXqSGxHfW6ldHnvckBCe3OjeR?= NUSwbmNJOjBizszN M{OxNVI1KGh? NYH6doJucW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= MVGyOFM3PjByNx?=
RKO M3Hwb2Z2dmO2aX;uJGF{e2G7 MoXENlAh|ryP MoSxNlQhcA>? NEj3VY5qdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw NFjrWHQzPDN4NkCwOy=>
U2OS  MnfWSpVv[3Srb36gRZN{[Xl? NYi3eY1mOjBizszN MYmyOEBp NVG5fmg5cW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44> MnHhNlQ{PjZyMEe=
RKO NX3QOnlqTnWwY4Tpc44hSXO|YYm= MoW4NlAh|ryP NHPPd5UzPCCq NEPzbG1qdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> M2\sdlI1OzZ4MEC3
SMMC-7721  M1XofWNmdGxiVnnhZoltcXS7IFHzd4F6 M{nKN|EvOjVvMkCg{txO NWT3VYk6OjRxNEivO|IhcA>? NFHESGVFVVOR Mlu0bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= NUTlUYQzOjR{OE[zNVI>
HuH-7 NGHud5RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4PhTVEvOjVvMkCg{txO NXLGVJB4OjRxNEivO|IhcA>? Mn\OSG1UVw>? MWLpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NImz[WUzPDJ6NkOxNi=>
SMMC-7721  M1PIbWFxd3C2b4Ppd{BCe3OjeR?= NVq2eXg3OjBizszN NEDVTm41QCCq NYP5XIxuTE2VTx?= NHvZNJFqdmS3Y3XzJIFxd3C2b4Ppdy=> M3TuSVI1Ojh4M{Gy
HuH-7 M3O4S2Fxd3C2b4Ppd{BCe3OjeR?= M1rpU|IxKM7:TR?= M4jIN|Q5KGh? M1vMNWROW09? MnXYbY5lfWOnczDhdI9xfG:|aYO= Mk\ONlQzQDZ|MUK=
SMMC-7721  NF3telZHfW6ldHnvckBCe3OjeR?= M3;TcVExKM7:TR?= MX6zOkBp M3rLUmROW09? NYHHcY1D\G:5bj3y[Yd2dGG2ZYOgeIhmKHC{b4TlbY4h\XiycnXzd4lwdiCuZY\lcEBw\iCyaH;zdIhwNVOnckO5Nk1xPTN? MWGyOFI5PjNzMh?=
HuH-7 NGDS[m9HfW6ldHnvckBCe3OjeR?= NYnJU4Q5OTBizszN M2jIWlM3KGh? M3eyN2ROW09? MWrkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> NYPWcmJDOjR{OE[zNVI>
AT2 MlzUSpVv[3Srb36gRZN{[Xl? MmfqOU8yOCEQvF2= NVn6SllMdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= MWiyOFI1ODJyMx?=
REH Mo\LSpVv[3Srb36gRZN{[Xl? MWS1M|ExKM7:TR?= MoC2cIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? NFna[YEzPDJ2MEKwNy=>
UoCB6 MXfGeY5kfGmxbjDBd5NigQ>? NFK2N3Q2NzFyIN88US=> NGLOe|Jt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= NIXrOYszPDJ2MEKwNy=>
AT2 MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkLtNE0zPSEQvF2= NF3Qcm9qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYXhXJhtOjR{NECyNFM>
REH NIH0NYFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFPiV2wxNTJ3IN88US=> MUDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NFPrS20zPDJ2MEKwNy=>
UoCB6 MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHnQbmwxNTJ3IN88US=> NHT3dWNqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NIr0SHEzPDJ2MEKwNy=>
A2780 NU\GVm5qTnWwY4Tpc44hSXO|YYm= NFTrNnE2NzFyL{KwJO69VQ>? NVL2fJc{OjRiaB?= M3jNe5VxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi MmPPNlQyOzZzNEe=
H460 MoD0SpVv[3Srb36gRZN{[Xl? MXi1M|ExNzJyIN88US=> MUWyOEBp MY\1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? MkDuNlQyOzZzNEe=
Lovo  MnTpSpVv[3Srb36gRZN{[Xl? Ml;uOU8yOC9{MDFOwG0> M13QV|I1KGh? M4GxcJVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi M{joRlI1OTN4MUS3
A2780 NUHqTo5HSXCxcITvd4l{KEG|c3H5 MXy1M|ExNzJyIN88US=> NX3a[IozOjRiaB?= NXPUOot2\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? NIP4XnMzPDF|NkG0Oy=>
H460 NFrLRlNCeG:ydH;zbZMhSXO|YYm= M2nvVFUwOTBxMkCg{txO M17FPFI1KGh? M{XpPIVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN MnewNlQyOzZzNEe=
Lovo  MWXBdI9xfG:|aYOgRZN{[Xl? M2j4cVUwOTBxMkCg{txO NEnsNZUzPCCq MnzX[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> NVXyeXk6OjRzM{[xOFc>

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID